Liquidia Corporation's Market Performance and Future Prospects

Core Insights - Liquidia Corporation is focused on developing therapies for pulmonary arterial hypertension and has received a bullish price target of $55 from Jefferies, indicating a potential increase of about 48.57% from its trading price of $37.02 [1][6] Stock Performance - Recently, Liquidia's stock price increased by 9.1%, reaching a high of $34.57 and closing at $34.65, with a trading volume of approximately 1.89 million shares, a 14% increase from the average session volume [2] - The stock is currently priced at $37.74, reflecting an increase of 3.11% or $1.14, with fluctuations between $35.28 and $38.19 during the trading day [4] - Over the past year, the stock has reached a high of $39.16 and a low of $11.26, with a market capitalization of approximately $3.22 billion [5] Financial Performance - Liquidia reported preliminary net sales for Q4 of YUTREPIA at approximately $90.1 million, with full-year sales projected to be around $148.3 million for 2025 [3] - The company achieved a positive cash flow exceeding $30 million in Q4 and has approximately $190.7 million in cash on hand [3][6] Commercial Metrics - Since the launch, Liquidia has recorded over 2,800 unique prescriptions, with more than 2,200 patients starting treatment, resulting in a prescription-to-start conversion rate of approximately 85% [4] - The expanding prescriber base supports expectations for durable revenue growth [4]